comparemela.com

Latest Breaking News On - Lankenau heart - Page 1 : comparemela.com

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years

Basel ramlawiCorevalve evolutNina goodheartMedtronic evolutDavidj cohenOutcomes researchAcademic affairs at stCardiovascular research foundationColumbia universityCardiovascular research technologiesLankenau heart instituteCardiothoracic surgery at main line health systemEvolut low riskEvolut low risk trialSenior vice presidentStructural heart

Medtronic has positive Evolut TAVR data

Medtronic (NYSE: MDT) today reported two different datasets that support its Evolut transcatheter aortic valve replacement (TAVR) system.

Basel ramlawiDavidj cohenNina goodheartCorevalve evolutCardiovascular research foundationCardiovascular research technologiesMain line health systemLankenau heart instituteStructural heartCardiovascular portfolioCardiovascular researchLankenau heart

Multi-Specialty Carotid Alliance (MSCA) Applauds The Centers For Medicare And Medicaid Services (CMS) National Coverage Decision For Stenting Of The Carotid Arteries

/PRNewswire/ On October 11th, The Centers for Medicare and Medicaid Services (CMS) announced a new national coverage decision (NCD) for stenting of the.

United statesChris metzgerChristopher whiteTudor jovinGary roubinThomas brottKenneth rosenfieldWilliam graySean lydenDanielg clairAdnan siddiquiSpecialty carotid allianceMain line healthOchsner clinical schoolBuffalo kaleida healthAnalysis group

Anthos Therapeutics Announces Abelacimab Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with AFib

Anthos Therapeutics has announced that Abelacimab has received FDA Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

United statesUnited kingdomSouth koreaColl cardiolDan bloomfieldWilliam wikoff smithThromb haemostPeter koweyAmerican society of clinical oncology annual meetingLankenau heart instituteCardiovascular researchDrug administrationNational blood clot allianceProgram in cancer associated thrombosisCirculation researchAnthos therapeutics

Disrupt PAD III Trial Demonstrates Safety and Effectiveness of Intravascular Lithotripsy for Peripheral Artery Calcification

First multi-center, randomized controlled study provides the largest long-term evidence for the treatment of heavily calcified femoropopliteal lesions

United statesWilliama grayChandan devireddyJuanf granadaSociety for cardiovascular angiography interventionsClinical events committeeLankenau heart institute main line healthCardiovascular angiographyLankenau heartMain line healthPeripheral artery calcificationRandomized disruptBalloon catheter contentDrug coated balloonsCatheter comparison chartDrug eluting balloons

vimarsana © 2020. All Rights Reserved.